文献速递胸部肿瘤放疗姑息放疗与转移瘤

广泛期小细胞肺癌治疗前总淋巴细胞计数与中性粒细胞/淋巴细胞比的预后意义

Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer.
PubMed 文献 · Radiother Oncol · 2018-02-02

该研究纳入1998—2015年治疗的252例广泛期小细胞肺癌(ES-SCLC)患者,评估治疗前总淋巴细胞计数(TLC)和中性粒细胞/淋巴细胞比(NLR)与总生存(OS)的关系。多因素分析显示低TLC和高NLR均预测更差生存,提示二者可用于患者分层。

要点

  • 治疗前TLC≤1.5×10³/µL者中位OS为9.8个月,高于此值为12.0个月。
  • 治疗前NLR>4.0者中位OS为9.4个月,不高于此值为13.9个月。
  • 低TLC和高NLR是多因素分析中独立的不良预后因素。

核心结论

  • 治疗前TLC和NLR可能有助于对ES-SCLC患者进行分层以指导治疗策略。

研究设计与样本

  • 回顾性分析252例1998—2015年治疗的ES-SCLC患者,评估治疗前血液指标及临床因素与OS的关系,单因素显著因素纳入多因素Cox模型。

主要发现

  • 治疗前TLC低于正常(<1.0×10³/µL)者58例(23%)。
  • 全组中位OS为11.0个月,TLC≤1.5×10³/µL者中位OS为9.8个月对12.0个月。
  • 治疗前NLR>4.0者中位OS为9.4个月对13.9个月。
  • 多因素分析显示低TLC(HR 0.734,95%CI 0.565-0.955,P=0.021)和高NLR(HR 1.521,95%CI 1.172-1.976,P=0.002)预测更差生存。
  • 年龄>63岁、男性、体能状态≥2、化疗周期<4、放疗剂量<45 Gy及未行PCI亦预测更差OS(P<0.05)。

临床怎么用

  • 在ES-SCLC患者治疗前可检测TLC和NLR,辅助识别预后较差、可能需要强化治疗或密切随访的人群。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated pretreatment total lymphocyte count (TLC, marker of immunosuppression), neutrophil-to-lymphocyte ratio (NLR, marker of inflammation), and overall survival (OS) in patients with extensive-stage small-cell lung cancer (ES-SCLC). METHODS: Pretreatment blood characteristics, age, sex, performance status, race, stage (M1a vs. M1b), number and location of metastases, weight loss, smoking status, chemotherapy cycles (<4 vs. ≥4), thoracic radiotherapy dose (<45 vs. ≥45 Gy), and receipt of prophylactic cranial irradiation (PCI) were evaluated in 252 patients with ES-SCLC treated in 1998-2015. Factors significant in univariate analysis were selected as covariates for a multivariate Cox model. RESULTS: Pretreatment TLC was below normal (<1.0 × 103/µL) in 58 patients (23%). Median OS time was 11.0 months and was worse for those with TLC ≤ 1.5 × 103/µL (9.8 vs. 12.0 months) and pretreatment NLR > 4.0 (9.4 vs. 13.9 months). Multivariate analysis identified low TLC (hazard ratio [HR] 0.734, 95% confidence interval [CI] 0.565-0.955, P = 0.021) and high NLR (HR 1.521, 95% CI 1.172-1.976, P = 0.002) as predicting inferior survival. Age (>63 y), sex (male), performance status (≥2), chemotherapy cycles (<4), radiation dose (<45 Gy), and no PCI also predicted worse OS (P < 0.05). CONCLUSIONS: Pretreatment TLC and NLR may be useful for stratifying patients with ES-SCLC for treatment approaches.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Suzuki R, Lin SH, Wei X, et al. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol. 2018. PMID: 29398150. doi:10.1016/j.radonc.2017.12.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。